Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc. (formerly Nasdaq: THTX) generates news primarily as a commercial-stage specialty biopharmaceutical company focused on HIV-related therapies and corporate transactions. Company press releases and regulatory reports highlight developments in its product portfolio, scientific presentations, financial performance, and significant corporate events, including its acquisition by an affiliate of Future Pak.
News coverage for Theratechnologies includes updates on tesamorelin for injection and its commercial formulations. In 2025, the company announced the availability of EGRIFTA WR (tesamorelin) for injection in the United States for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy, following FDA approval earlier that year. Releases also describe the planned transition from EGRIFTA SV to EGRIFTA WR and provide information on patient support initiatives related to this change.
Another key stream of news involves scientific and clinical data. Theratechnologies has reported poster presentations at the American Conference for the Treatment of HIV (ACTHIV), including analyses from the VAMOS study on excess visceral abdominal fat and muscle quality in people with HIV, and a case series examining combined use of tesamorelin and GLP-1 receptor agonists. These items give readers insight into how the company positions its therapies within evolving HIV care.
Theratechnologies’ news flow has also featured financial reporting and strategic transactions. Quarterly results press releases summarize revenue from products such as EGRIFTA SV and Trogarzo, cost of goods sold, research and development spending, and adjusted EBITDA, with references to detailed MD&A and interim financial statements. In 2025, the company announced a definitive arrangement agreement with CB Biotechnology, an affiliate of Future Pak, followed by shareholder approval, court approval, and completion of the acquisition. Subsequent communications describe the expected delisting of its shares from the Toronto Stock Exchange and Nasdaq and its transition to a privately held company.
Investors and observers using this news page can review historical announcements on product availability, clinical data, financial performance, and the completed acquisition. This provides context on how Theratechnologies evolved from a dual-listed biopharmaceutical issuer into a privately held company affiliated with Future Pak.
Theratechnologies Inc. (NASDAQ: THTX) appointed Elif McDonald as the new Senior Director of Investor Relations. McDonald brings over 20 years of experience in capital markets and investor relations, particularly in biotech and pharmaceuticals. CEO Paul Lévesque expressed confidence in her ability to enhance investor engagement and raise awareness of the company’s commercial portfolio and research pipeline. This appointment aims to strengthen the company’s visibility and communication strategies in capital markets.
MONTREAL, May 10, 2022 - Theratechnologies (TSX: TH, NASDAQ: THTX) held its annual meeting where shareholders elected Board candidates and appointed KPMG as auditors. Resolutions for a shareholder rights plan and amendments to the share option plan were approved. The company reported successful revenue growth and is building a research pipeline in oncology, aiming for strong returns for shareholders. Chair Dawn Svoronos emphasized the need for a balanced approach between commercial operations and research development for maximizing shareholder value.
Theratechnologies announced the initiation of patient enrollment in a basket trial for TH1902, its investigational peptide drug conjugate aimed at treating solid tumors expressing Sortilin. The established dose for this phase 1b study is 300 mg/m2, which is 1.5 times the therapeutic dose of docetaxel, without dose-limiting toxicities observed. The study will assess the efficacy and safety of TH1902 in various cancers including HR+ Breast Cancer and Melanoma. This development follows promising pre-clinical results suggesting TH1902 could significantly enhance docetaxel delivery into cancer cells.
Theratechnologies (THTX) has announced it will cease commercialization of Trogarzo® in Europe due to unsatisfactory pricing and reimbursement conditions. The company will focus on the North American market and return European rights to TaiMed Biologics within 180 days. This decision involves restructuring its Dublin subsidiary, resulting in an estimated cash charge of US$1.5 to US$2 million and non-cash charges of about US$6.5 million. European sales, which represented less than 2% of overall revenues, will not impact the company's revenue guidance for fiscal year 2022.
Theratechnologies Inc. (NASDAQ: THTX) will present at the Bloom Burton & Co.’s Healthcare Investor Conference 2022 on Tuesday, May 3, 2022, starting at 1:30 PM ET. The event will take place at the Metro Toronto Convention Centre, Track B, featuring 66 leading healthcare companies.
Investors can receive corporate updates and engage in one-on-one meetings with company management. Registration is mandatory for participation. More details are available on Theratechnologies' official website.
Theratechnologies (THTX) reported a 20% increase in consolidated sales for Q1 2022, driven by a 34.7% rise in EGRIFTA SV® sales, totaling $11.7 million. Overall revenues reached $18.6 million, up from $15.4 million in Q1 2021. R&D expenses surged by 64.6% to $8 million due to oncology program investments. The company is advancing its TH1902 clinical trial and aims for a basket study enrollment in 2022. However, delays in filing an sBLA for the F8 formulation due to supply issues were noted, alongside a net loss of $9 million, worsening from $5.9 million the prior year.
Theratechnologies (THTX) announced three poster presentations at the 2022 AACR Annual Meeting, highlighting promising preclinical data for its lead product TH1902. This drug targets sortilin-expressing cancers, showing significant tumor growth inhibition in triple-negative breast and ovarian cancer models. Key findings demonstrated an 80% reduction in tumor growth compared to standard treatments. Additionally, TH1902 exhibited superior efficacy in melanoma and endometrial cancer models. The company anticipates moving forward with further clinical trials, pending positive results.
Theratechnologies has announced it will report its first quarter financial results for fiscal 2022, ending February 28, 2022, on April 13, 2022. A conference call will follow at 8:30 a.m. (ET) to discuss the results and provide business updates. The call will feature Paul Lévesque, President & CEO, with a Q&A session for participants. Access details include a toll-free dial-in number and a webcast link. Audio replay options will be available for later listening.
Theratechnologies (THTX) announced acceptance of three poster abstracts for the 2022 AACR Annual Meeting, showcasing TH1902 preclinical data. These studies reveal the drug's ability to inhibit tumor growth in human cancer stem-like cells (CD133+) in triple-negative breast and ovarian cancers. Additional findings demonstrate TH1902's efficacy against ovarian and endometrial cancer xenografts and its inhibitory effects on melanoma growth and lung metastasis in syngeneic mice. Presentations will take place on April 11, 2022, in New Orleans.
Theratechnologies (THTX) reported a 5.7% increase in FY2021 consolidated sales, totaling $69.8 million, driven primarily by strong EGRIFTA SV® performance. Revenue guidance for FY2022 is projected between $79 million and $84 million, indicating growth of 13%-20% compared to FY2021. New patient enrollments surged 24%. The company is advancing its lead oncology asset, TH1902, towards Phase 1/Part B expansion, as it seeks out-licensing partners in Greater China. However, Trogarzo® sales declined 28.3% in Q4 2021 due to reimbursement issues in France.
FAQ
What is the current stock price of Theratechnologies (THTX)?
What is the market cap of Theratechnologies (THTX)?
